Clinical Data

Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data

BioSpace

By inhibiting the APRIL cascade, Otsuka Pharmaceuticals' Voyxact slowed kidney function decline in patients with IgAN, opening up a potential path for full approval while also reading through to Verte

Rare Disease

Read full story

pharminent June 5, 2026 (Last updated: June 5, 2026)

BioSpace

By inhibiting the APRIL cascade, Otsuka Pharmaceuticals’ Voyxact slowed kidney function decline in patients with IgAN, opening up a potential path for full approval while also reading through to Verte

Rare Disease

Read full story

Related Stories

ADC Therapeutics slumps on cancer drug safety scare

Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity

Legend surges on early data for ‘in vivo’ lymphoma cell therapy

You May Have Missed

Lilly and Novo face off at ADA 2026 as others seek to compete in obesity

Medicare Advantage in 2026: Enrollment Update and Key Trends

The next FDA commissioner must be a champion for gene therapies

Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data